Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

Research output: Contribution to journalArticle

Standard

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. / van der Velden, VHJ; van der Sluijs-Geling, A; Gibson, BES; Marvelde, JGT; Hoogeveen, PG; Hop, WCJ; Wheatley, Keith; Bierings, MB; Schuurhuis, GJ; de Graaf, SSN; van Wering, ER; van Dongen, JJM.

In: Leukemia, Vol. 24, No. 9, 01.09.2010, p. 1599-1606.

Research output: Contribution to journalArticle

Harvard

van der Velden, VHJ, van der Sluijs-Geling, A, Gibson, BES, Marvelde, JGT, Hoogeveen, PG, Hop, WCJ, Wheatley, K, Bierings, MB, Schuurhuis, GJ, de Graaf, SSN, van Wering, ER & van Dongen, JJM 2010, 'Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol', Leukemia, vol. 24, no. 9, pp. 1599-1606. https://doi.org/10.1038/leu.2010.153

APA

van der Velden, VHJ., van der Sluijs-Geling, A., Gibson, BES., Marvelde, JGT., Hoogeveen, PG., Hop, WCJ., Wheatley, K., Bierings, MB., Schuurhuis, GJ., de Graaf, SSN., van Wering, ER., & van Dongen, JJM. (2010). Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia, 24(9), 1599-1606. https://doi.org/10.1038/leu.2010.153

Vancouver

Author

van der Velden, VHJ ; van der Sluijs-Geling, A ; Gibson, BES ; Marvelde, JGT ; Hoogeveen, PG ; Hop, WCJ ; Wheatley, Keith ; Bierings, MB ; Schuurhuis, GJ ; de Graaf, SSN ; van Wering, ER ; van Dongen, JJM. / Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. In: Leukemia. 2010 ; Vol. 24, No. 9. pp. 1599-1606.

Bibtex

@article{d32081d1c766468f87e15802945dc863,
title = "Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol",
abstract = "Analysis of minimal residual disease (MRD) in childhood acute myeloid leukemia (AML) may predict for clinical outcome. MRD levels were assessed by flowcytometric immunophenotyping in 94 children with AML enrolled into a single trial (United Kingdom Medical Research Council AML12 and similar Dutch Childhood Oncology Group ANLL97). An aberrant immunophenotype could be detected in 94% of patients. MRD levels after the first course of chemotherapy predicted for clinical outcome: 3-year relapse-free survival was 85% +/- 8% (s.e.) for MRD-negative patients (MRD <0.1%), 64% +/- 10% for MRD-low-positive patients (0.1% = 0.5%; P <0.001), whereas overall survival was 95% +/- 5%, 70% +/- 10% and 40% +/- 13%, respectively, (P <0.001). Multivariate analysis allowing for age, karyotype, FLT3-internal tandem duplications and white blood cell count at diagnosis showed that MRD after the first course of chemotherapy was an independent prognostic factor. Although comparison of paired diagnosis-relapse samples (n = 23) showed immunophenotypic shifts in 91% of cases, this did not hamper MRD analysis. In conclusion, flowcytometric MRD detection is possible in children with AML. The level of MRD after the first course of chemotherapy provides prognostic information that may be used to guide therapy. Leukemia (2010) 24, 1599-1606; doi: 10.1038/leu.2010.153;published online 29 July 2010",
keywords = "flowcytometry, minimal residual disease, childhood acute myeloid leukemia, relapse, outcome, immunophenotyping",
author = "{van der Velden}, VHJ and {van der Sluijs-Geling}, A and BES Gibson and JGT Marvelde and PG Hoogeveen and WCJ Hop and Keith Wheatley and MB Bierings and GJ Schuurhuis and {de Graaf}, SSN and {van Wering}, ER and {van Dongen}, JJM",
year = "2010",
month = sep,
day = "1",
doi = "10.1038/leu.2010.153",
language = "English",
volume = "24",
pages = "1599--1606",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "9",

}

RIS

TY - JOUR

T1 - Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

AU - van der Velden, VHJ

AU - van der Sluijs-Geling, A

AU - Gibson, BES

AU - Marvelde, JGT

AU - Hoogeveen, PG

AU - Hop, WCJ

AU - Wheatley, Keith

AU - Bierings, MB

AU - Schuurhuis, GJ

AU - de Graaf, SSN

AU - van Wering, ER

AU - van Dongen, JJM

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Analysis of minimal residual disease (MRD) in childhood acute myeloid leukemia (AML) may predict for clinical outcome. MRD levels were assessed by flowcytometric immunophenotyping in 94 children with AML enrolled into a single trial (United Kingdom Medical Research Council AML12 and similar Dutch Childhood Oncology Group ANLL97). An aberrant immunophenotype could be detected in 94% of patients. MRD levels after the first course of chemotherapy predicted for clinical outcome: 3-year relapse-free survival was 85% +/- 8% (s.e.) for MRD-negative patients (MRD <0.1%), 64% +/- 10% for MRD-low-positive patients (0.1% = 0.5%; P <0.001), whereas overall survival was 95% +/- 5%, 70% +/- 10% and 40% +/- 13%, respectively, (P <0.001). Multivariate analysis allowing for age, karyotype, FLT3-internal tandem duplications and white blood cell count at diagnosis showed that MRD after the first course of chemotherapy was an independent prognostic factor. Although comparison of paired diagnosis-relapse samples (n = 23) showed immunophenotypic shifts in 91% of cases, this did not hamper MRD analysis. In conclusion, flowcytometric MRD detection is possible in children with AML. The level of MRD after the first course of chemotherapy provides prognostic information that may be used to guide therapy. Leukemia (2010) 24, 1599-1606; doi: 10.1038/leu.2010.153;published online 29 July 2010

AB - Analysis of minimal residual disease (MRD) in childhood acute myeloid leukemia (AML) may predict for clinical outcome. MRD levels were assessed by flowcytometric immunophenotyping in 94 children with AML enrolled into a single trial (United Kingdom Medical Research Council AML12 and similar Dutch Childhood Oncology Group ANLL97). An aberrant immunophenotype could be detected in 94% of patients. MRD levels after the first course of chemotherapy predicted for clinical outcome: 3-year relapse-free survival was 85% +/- 8% (s.e.) for MRD-negative patients (MRD <0.1%), 64% +/- 10% for MRD-low-positive patients (0.1% = 0.5%; P <0.001), whereas overall survival was 95% +/- 5%, 70% +/- 10% and 40% +/- 13%, respectively, (P <0.001). Multivariate analysis allowing for age, karyotype, FLT3-internal tandem duplications and white blood cell count at diagnosis showed that MRD after the first course of chemotherapy was an independent prognostic factor. Although comparison of paired diagnosis-relapse samples (n = 23) showed immunophenotypic shifts in 91% of cases, this did not hamper MRD analysis. In conclusion, flowcytometric MRD detection is possible in children with AML. The level of MRD after the first course of chemotherapy provides prognostic information that may be used to guide therapy. Leukemia (2010) 24, 1599-1606; doi: 10.1038/leu.2010.153;published online 29 July 2010

KW - flowcytometry

KW - minimal residual disease

KW - childhood acute myeloid leukemia

KW - relapse

KW - outcome

KW - immunophenotyping

U2 - 10.1038/leu.2010.153

DO - 10.1038/leu.2010.153

M3 - Article

VL - 24

SP - 1599

EP - 1606

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 9

ER -